Lipids uniquely alter secondary structure and toxicity of lysozyme aggregates.


Journal

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484

Informations de publication

Date de publication:
10 2022
Historique:
revised: 03 08 2022
received: 31 05 2022
accepted: 29 08 2022
entrez: 12 9 2022
pubmed: 13 9 2022
medline: 14 9 2022
Statut: ppublish

Résumé

Abrupt aggregation of misfolded proteins is a hallmark of the large group of amyloid pathologies that include diabetes type 2, Alzheimer and Parkinson's diseases. Protein aggregation yields oligomers and fibrils, β-sheet-rich structures that exert cell toxicity. Microscopic examination of amyloid deposits reveals the presence of lipids membranes, which suggests that lipids can be involved in the process of pathogenic protein assembly. In this study, we show that lipids can uniquely alter the aggregation rates of lysozyme, a protein that is associated with systemic amyloidosis. Specifically, cardiolipin (CL), ceramide (CER), and sphingomyelin (SM) accelerate, phosphatidylcholine (PC) strongly inhibits, whereas phosphatidylserine (PS) has no effect on the rate of protein aggregation. Furthermore, lipids uniquely alter the secondary structure of lysozyme aggregates. Furthermore, we found that lysozyme aggregates grown in the presence of CL, CER, SM, PS, and CL:PC mixtures exert significantly lower production of reactive oxygen species and mitochondrial dysfunction compared to lysozyme:PC aggregates and lysozyme fibrils grown in the lipid-free environment. These findings suggest that a change in the lipid composition of cell membranes, which is taken place upon neurodegeneration, may trigger the formation of toxic protein species that otherwise would not be formed.

Identifiants

pubmed: 36094052
doi: 10.1096/fj.202200841R
pmc: PMC10427241
mid: NIHMS1921596
doi:

Substances chimiques

Amyloid 0
Antiviral Agents 0
Cardiolipins 0
Protein Aggregates 0
Muramidase EC 3.2.1.17

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e22543

Subventions

Organisme : NIGMS NIH HHS
ID : R35 GM142869
Pays : United States

Informations de copyright

© 2022 Federation of American Societies for Experimental Biology.

Références

Annu Rev Biochem. 2017 Jun 20;86:27-68
pubmed: 28498720
Biochim Biophys Acta. 2008 Jul-Aug;1777(7-8):794-9
pubmed: 18420023
Chem Rev. 2017 Apr 12;117(7):5146-5173
pubmed: 27958707
Biochem J. 1983 Apr 1;211(1):155-62
pubmed: 6870819
Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11282-6
pubmed: 8248242
J Biol Chem. 2001 Jan 26;276(4):2380-6
pubmed: 11060312
Commun Biol. 2018 May 3;1:44
pubmed: 30271927
ACS Nano. 2020 May 26;14(5):5213-5222
pubmed: 32159944
Commun Biol. 2021 Jan 4;4(1):19
pubmed: 33398040
Proc Natl Acad Sci U S A. 2015 Apr 21;112(16):E1994-2003
pubmed: 25855634
J Phys Chem Lett. 2022 Mar 17;13(10):2467-2473
pubmed: 35266717
Elife. 2018 Jul 03;7:
pubmed: 29969391
Chem Commun (Camb). 2010 Oct 14;46(38):7154-6
pubmed: 20820535
J Am Chem Soc. 2007 Sep 12;129(36):11002-3
pubmed: 17705492
Anal Chem. 2020 Aug 18;92(16):11297-11304
pubmed: 32683857
Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):7065-70
pubmed: 27298346
ACS Omega. 2019 Jul 18;4(7):12308-12318
pubmed: 31460348
ACS Nano. 2018 Jul 24;12(7):6612-6619
pubmed: 29932670
FEBS Lett. 2022 Jun;596(11):1424-1433
pubmed: 35510803
Front Cell Neurosci. 2019 May 01;13:175
pubmed: 31118888
Nat Rev Mol Cell Biol. 2008 Feb;9(2):112-24
pubmed: 18216768
Annu Rev Phys Chem. 2011;62:279-99
pubmed: 21219138
Protein Sci. 2007 May;16(5):815-32
pubmed: 17400924
Protein Pept Lett. 2011 Mar;18(3):230-40
pubmed: 20858207
Biochem Biophys Res Commun. 2012 May 25;422(1):97-102
pubmed: 22564742
J Phys Chem Lett. 2022 May 26;13(20):4563-4569
pubmed: 35580189
Nat Commun. 2015 Jul 28;6:7831
pubmed: 26215704
Sci Rep. 2016 Apr 14;6:24526
pubmed: 27075649
J Phys Chem Lett. 2018 Sep 6;9(17):5125-5129
pubmed: 30133296
Nat Commun. 2018 Sep 6;9(1):3609
pubmed: 30190461
Biochim Biophys Acta. 2007 Sep;1767(9):1073-101
pubmed: 17692815
Cell. 2012 May 25;149(5):1048-59
pubmed: 22632969
J Am Chem Soc. 2014 Feb 12;136(6):2302-12
pubmed: 24484302
J Am Chem Soc. 2014 Jun 25;136(25):8947-56
pubmed: 24884889
Nat Rev Mol Cell Biol. 2018 Dec;19(12):755-773
pubmed: 30237470
J Am Chem Soc. 2008 Jan 9;130(1):309-17
pubmed: 18067295
J Phys Chem C Nanomater Interfaces. 2022 Mar 3;126(8):4157-4162
pubmed: 35719853
Biochim Biophys Acta. 2013 Oct;1828(10):2328-38
pubmed: 23746423
J Mol Biol. 2006 Jan 6;355(1):63-71
pubmed: 16303137
J Parkinsons Dis. 2017;7(3):433-450
pubmed: 28671142
Front Neurosci. 2019 Apr 11;13:328
pubmed: 31031582
J Chem Phys. 2016 May 14;144(18):184901
pubmed: 27179503
Nat Rev Mol Cell Biol. 2014 Jun;15(6):384-96
pubmed: 24854788
J Phys Chem Lett. 2021 May 13;12(18):4407-4414
pubmed: 33945282
J Am Chem Soc. 2007 Jun 6;129(22):6972-3
pubmed: 17500518
Analyst. 2015 Aug 7;140(15):4967-80
pubmed: 26042229
Proc Natl Acad Sci U S A. 2009 May 5;106(18):7443-8
pubmed: 19376973
Cell Rep. 2020 Sep 15;32(11):108132
pubmed: 32937123
Biochim Biophys Acta Proteins Proteom. 2019 May;1867(5):483-491
pubmed: 30287222
Nat Chem Biol. 2015 Mar;11(3):229-34
pubmed: 25643172
Chem Soc Rev. 2020 Jun 7;49(11):3315-3347
pubmed: 32424384
Nat Commun. 2020 Jun 10;11(1):2945
pubmed: 32522983
Trends Cell Biol. 2020 May;30(5):341-353
pubmed: 32302547

Auteurs

Mikhail Matveyenka (M)

Department of Biochemistry and Biophysics, Texas A&M University, College Station, Texas, USA.

Kiryl Zhaliazka (K)

Department of Biochemistry and Biophysics, Texas A&M University, College Station, Texas, USA.

Stanislav Rizevsky (S)

Department of Biochemistry and Biophysics, Texas A&M University, College Station, Texas, USA.
Department of Biotechnology, Binh Duong University, Thu Dau Mot, Vietnam.

Dmitry Kurouski (D)

Department of Biochemistry and Biophysics, Texas A&M University, College Station, Texas, USA.
Department of Biomedical Engineering, Texas A&M University, College Station, Texas, USA.

Articles similaires

Animals Swine Antiviral Agents Swine Diseases Coronavirus Infections
alpha-Synuclein Humans Animals Mice Lewy Body Disease
Humans Carcinoma, Hepatocellular Liver Neoplasms Aged United States

Amyloid accelerator polyphosphate fits as the mystery density in α-synuclein fibrils.

Philipp Huettemann, Pavithra Mahadevan, Justine Lempart et al.
1.00
Polyphosphates alpha-Synuclein Humans Amyloid Molecular Dynamics Simulation

Classifications MeSH